News Archives
Monday, June 11, 2007
Chenomx and GeneGo Offer Metabolomics Data
Integration
Chenomx, Inc., a leading provider of
software and compound libraries for NMR-based metabolomics, and
GeneGo, Inc., a worldwide leader in data analysis solutions for
systems biology and pathway analysis, are pleased to announce a
partnership to provide metabolomics data integration between their
software products.
This partnership combines Chenomx’s powerful and easy-to-use metabolomics software, Chenomx NMR Suite, with GeneGo’s MetaCore and MetaDrug Discovery platform, providing researchers with the ability to perform sophisticated pathway analysis and visualization.
“Chenomx’s partnership with GeneGo offers several significant advantages to our shared customers,” explains Jack Newton, Director of Product Development for Chenomx. “First, our customers will now be able to combine Chenomx NMR Suite’s powerful metabolite identification and quantification capabilities with GeneGo’s pathway analysis tools, thereby improving their interpretation and understanding of the underlying biology. This integration also allows our customers to integrate genomic and proteomic data sources with their Chenomx metabolomics data.”
“We initiated this partnership based on customer requests for seamless functional analysis of their NMR and mass spec metabolomics data,” said Julie Bryant VP of business development. “Metabolic data is hugely important in diagnostics and drug discovery, as any major disease fundamentally affects core biochemical pathways. Yet, MetaCore/MetaDrug is the only product in the field which enables direct parsing, pathway and network analysis of human metabolic data and its integration with genomics, proteomics and genetic data. Now, our customers will have this functionality accessed directly from Chenomx software”.
Wednesday, May 2, 2007
Chenomx Inc. Receives Patents for NMR-based Automated
Mixture Analysis Technology
Chenomx Inc., a leading provider of metabolic profiling
services and software, has been awarded two U.S. patents for its
innovative Nuclear Magnetic Resonance (NMR)-based mixture analysis
algorithms.
First made available to customers in 2001 through Chenomx NMR Suite, Chenomx’s flagship software product, Chenomx’s mixture analysis algorithms allow users to rapidly identify and quantify compounds in complex mixtures. Chenomx NMR Suite has been initially applied in the field of metabolomics, where it has been used to identify and quantify a broad range of metabolites in complex biofluid samples, including blood, urine and cell extracts.
“We are extremely happy to have the innovation and technical accomplishments that make up Chenomx’s technology platform recognized by the U.S. Patent Office,” says Neil Taylor, President and CEO of Chenomx.
The two patents describe the methods that are embodied in Chenomx NMR Suite for creating unique “signatures” of metabolites and using these signatures to deconvolve complex NMR spectra. These techniques allow complex, information-rich NMR spectra to be transformed into biologically meaningful metabolic profiles – lists of identified and quantified metabolites. In recognition of the innovation and unique nature of Chenomx’s methods, the U.S. Patent Office awarded Patent Nos. 7181348 and 7491069 to Chenomx Inc. on February 20, 2007 and March 13, 2007, respectively. Chenomx’s technology has been previously awarded two patents in the U.K., Patent Nos. 2390166 and 2410599, issued on August 3, 2005 and September 28, 2005, respectively.
Monday, March 26, 2007
Chenomx Inc. Announces Metabolic Profiling
Services
Chenomx Inc., a privately-held company
that develops proprietary technologies for identifying and
quantifying metabolites in complex biofluid mixtures, today
announced the debut of metabolic profiling services, making
Chenomx’s industry-leading metabolic profiling platform available
to the worldwide research community.
Chenomx’s metabolic profiling services enable users to
identify and quantify a broad range of metabolites in a number of
biofluids, including blood, urine and cell extracts. The
information contained in these metabolic profiles can be used to
monitor the efficacy of potential drug candidates, to identify
pathological reactions to potential drug candidates, and to
identify potential biomarkers for diagnostic or toxicological applications.
Chenomx’s metabolic profiling platform is a unique,
patented combination of hardware and software optimized for
identifying and quantifying metabolites in biofluids. Nuclear
Magnetic Resonance (NMR) spectrometers with field strengths of up
to 800 MHz form the hardware component of the platform, offering
high-throughput analysis and sensitive, quantitative, unbiased
detection of a broad range of metabolites. Chenomx’s patented NMR
mixture analysis algorithms transform information-rich but complex
NMR spectra into quantitative metabolic profiles. Chenomx’s
software technology is deployed and in use at many of the world’s
leading pharmaceuticals and academic research institutions.
“The launch of Chenomx’s metabolic profiling services will help us
bring Chenomx’s metabolic profiling technology to the broader
research community,” comments Neil Taylor, President and CEO of
Chenomx. “Research scientists can now leverage Chenomx’s patented
metabolic profiling technology without the need for in-house NMR
spectrometers and expertise.”
For additional information on Chenomx’s metabolic profiling
services, please visit www.chenomx.com/services.
November 6, 2006
Announcing Chenomx NMR Suite 5.0. Chenomx is pleased to announce the immediate availability of Chenomx NMR Suite 5.0. Learn more here.
June 5, 2006
Announcing Chenomx NMR Suite 4.5. Chenomx is pleased to announce the immediate availability of Chenomx NMR Suite 4.5. Learn more here.
April 24, 2006
Chenomx and Umetrics Partner to Provide an Enhanced
Metabolomics Analysis Platform
Chenomx, Inc., a leading provider of software and
compound libraries used to identify and quantify metabolites in
NMR spectra, and Umetrics AB, a worldwide leader in multivariate
analysis and modeling software, are pleased to announce a
partnership to provide a comprehensive metabolomics solution to
researchers worldwide.
This partnership combines Chenomx’s powerful and easy-to-use metabolic profiling software with Umetrics’ proven multivariate analysis software, providing researchers with a turn-key solution for discovering biologically relevant patterns in NMR spectra.
“Metabolomics researchers are faced with two key challenges,” explains Jack Newton, Director of Product Development for Chenomx. “First, they must analyze large NMR data sets, potentially consisting of thousands of NMR spectra, to find meaningful patterns in their data. Translating these patterns into biologically relevant information in the form of metabolite identification and quantification is the second key challenge. These two processes are tightly coupled, and the decision to partner with Umetrics to make the process as intuitive and as effortless as possible for the end-user was a natural one.”
Jan Wahlström, European CEO and Sales Manager, adds “This partnership is great news for scientists working in metabonomics and metabolomics as it provides them with a seamless interface between data collection and data analysis, allowing them to get on with the science.”
About Chenomx, Inc.
Chenomx, Inc. is a
privately-held Canadian company that specializes in the
development of complex mixture analysis software for broad
application in life science technologies. With world-class
expertise in NMR spectroscopy, pharmaceutical sciences, and
computer software, Chenomx offers a broad range of software
products and compound databases to support the metabolomics
communities' research efforts. Chenomx's flagship product, Chenomx
NMR Suite, provides a rich set of tools for identifying and
quantifying metabolites in complex NMR Spectra. More information
on Chenomx and its solutions is available at www.chenomx.com.
About Umetrics
Umetrics is a leading-edge
software company which supplies data analysis software and
training courses in multivariate analysis and design of
experiments. Umetrics provide solutions for both off-line and
on-line applications to a broad range of companies, particularly
from the pharmaceutical, biotech and chemical sectors. Umetrics
was recently acquired by MKS Instruments Inc (NASDAQ: MKSI), a
worldwide provider of monitoring and control technologies. For
more information about Umetrics solutions for Metabonomics, please
see www.umetrics.com
January 25, 2006
Infocom announced as Distributor of Chenomx Products in
Japan
Chenomx Inc. and Infocom Corporation announced an
agreement today which establishes Infocom as the independent
distributor of Chenomx products in Japan. Infocom, under the
terms of the agreement, will distribute Chenomx NMR Suite - a
sophisticated metabolic profiling software system used to discover
metabolic marker patterns for use in drug discovery, clinical
trails and clinical diagnostics.
“We are very excited about launching the distribution of
Chenomx’s state-of-the-art solutions to metabolomics researchers
in the Japanese market” said K. Ohgaki, General Manager of
Infocom's Bioscience department. “We hope that we will be able to
take advantage of this precious opportunity to further expand our
business area into a diagnostic field as well as metabolomics research.”
Neil Taylor, CEO of Chenomx Inc., echoed the enthusiasm
about the partnership. “This agreement allows us to quickly
introduce our products to a large group of researchers. Infocom’s
extensive experience in the Japanese market will give us the
representation we need to support Japanese research scientists”
About Infocom Corporation
Infocom
Corporation, headquartered in Tokyo, was founded in 1983. Infocom
is a comprehensive service IT company carrying out a wide range of
business centered on the areas of medical services. In the field
of biosciences, they have a strong emphasis on providing support
for drug discovery researchers. They offer a variety of solutions
including solutions to CCS, ADMET, data mining, statistical
analysis, proteome and genome analysis. For more information, see
www.infocom.co.jp/bio/admet/chenomx.html or contact info-science@infocom.co.jp.
About Chenomx Inc.
Chenomx Inc. is a
privately-held Canadian company that specializes in the
development of complex mixture analysis software for broad
application in life science technologies. With world-class
expertise in NMR spectroscopy, pharmaceutical sciences, and
computer software, Chenomx offers a broad range of software
products and compound databases to support the metabolomics
communities' research efforts. Chenomx's flagship product, Chenomx
NMR Suite, provides a rich set of tools for identifying and
quantifying metabolites in complex NMR Spectra. More information
on Chenomx Inc. and its solutions is available at www.chenomx.com
November 30, 2005
Announcing Chenomx NMR Suite 4.0. Chenomx is pleased to announce the immediate availability of Chenomx NMR Suite 4.0. Learn more here.
October 14, 2004
Chenomx Provides Analytic Platform for New $2.6m Magnetic Resonance Diagnostics Centre. A new $2.6 million centre at the University of Alberta could potentially save Canada's health care system millions of dollars through a simple, cost effective diagnostic test. The Magnetic Resonance Diagnostic Centre (MRDC), the only one of its kind in North America, is researching non-invasive routine diagnostic tests for a host of diseases that allows physicians to diagnose disease more quickly, monitor the health status of patients in hospitals and clinics, improve treatment monitoring, and potentially decrease drug complications. Chenomx Inc. is providing the software analysis platform for the MRDC.
April 13, 2004
Chenomx NMR Suite to be used as Metabolic Analysis Platform as part of $18m Genome Canada Grant. The Honourable Anne McLellan, Deputy Prime Minister and Minister of Public Safety and Emergency Preparedness and Member of Parliament for Edmonton West, and Dr. Henry Friesen, Chair of Genome Canada, today announced the approval of fourteen new large-scale applied-health genomics research projects totaling $123 million. Genome Prairie, which is managing and financing genomics infrastructure and research projects in the Prairie Provinces, will be receiving more than $18 million, shared between the two projects at the University of Alberta. Dr. David Wishart, one of the recipients of this award, will use the Chenomx NMR Suite metabolic profiling platform as a key part of his effort to map the human metabonome. For more information, see the press release on the Genome Canada web site.
April 6, 2004
Varian, Inc. Invests in Chenomx, Inc. Metabolomics Software Effort. Varian, Inc. (Nasdaq: VARI) and Chenomx, Inc. announced today that Varian, Inc. has made a strategic equity investment in Chenomx, Inc., a privately held company that is a leader in the rapidly growing field of metabolic profiling.